The use of compounded GLP-1 copies, often used for weight loss, is facing significant changes. Some reports indicate that the FDA is taking steps to limit or end the availability of these compounded medications, while others suggest that companies are exploring alternative approaches, such as microdosing or collaborations. The impact of these changes on patients who rely on these medications is uncertain, with some potentially facing limited access to affordable alternatives.